-
EP3413903
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3413903
| EP3413903 - SUBLINGUAL ANTIDEPRESSANT LOZENGE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 23.06.2023 Database last updated on 22.08.2024 | |
| Former | Examination is in progress Status updated on 20.10.2022 | ||
| Former | Request for examination was made Status updated on 16.11.2018 | ||
| Former | The international publication has been made Status updated on 18.08.2017 | Most recent event Tooltip | 23.06.2023 | Application deemed to be withdrawn | published on 26.07.2023 [2023/30] | Applicant(s) | For all designated states Synergistic Therapeutics, LLC 3415 Radio Road Suite 109 Naples, FL 34104 / US | [2018/51] | Inventor(s) | 01 /
SALCE, Anthony, H., Jr. 3415 Radio Road Ste. 109 Naples FL 34104 / US | 02 /
GREENWOOD, William 138 Patrick Drive Fairfield CT 06824 / US | 03 /
MISIR, Shivsankar 8795 Tamiami Trail E. Naples FL 34113 / US | [2018/51] | Representative(s) | Roberts, Michael Austin Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB | [2018/51] | Application number, filing date | 17750967.6 | 13.02.2017 | [2018/51] | WO2017US17674 | Priority number, date | US201662294590P | 12.02.2016 Original published format: US 201662294590 P | [2018/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017139768 | Date: | 17.08.2017 | Language: | EN | [2017/33] | Type: | A1 Application with search report | No.: | EP3413903 | Date: | 19.12.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.08.2017 takes the place of the publication of the European patent application. | [2018/51] | Search report(s) | International search report - published on: | US | 17.08.2017 | (Supplementary) European search report - dispatched on: | EP | 19.08.2019 | Classification | IPC: | A61K9/20, A61K31/135, A61P11/12, A23G3/34, A23G3/36 | [2019/38] | CPC: |
A61K9/0056 (EP,US);
A23G3/0053 (EP,US);
A23G3/36 (EP,US);
A23G3/364 (EP,US);
A61K31/135 (EP,US);
A61K9/2009 (EP,US);
|
| Former IPC [2018/51] | A61K36/61, A61P11/12 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/51] | Title | German: | ANTIDEPRESSIVE SUBLINGUALE LUTSCHTABLETTE | [2018/51] | English: | SUBLINGUAL ANTIDEPRESSANT LOZENGE | [2018/51] | French: | TABLETTE SUBLINGUALE D'ANTIDÉPRESSEUR | [2018/51] | Entry into regional phase | 07.09.2018 | National basic fee paid | 07.09.2018 | Search fee paid | 07.09.2018 | Designation fee(s) paid | 07.09.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 07.09.2018 | Examination requested [2018/51] | 16.03.2020 | Amendment by applicant (claims and/or description) | 19.10.2022 | Despatch of a communication from the examining division (Time limit: M04) | 01.03.2023 | Application deemed to be withdrawn, date of legal effect [2023/30] | 22.03.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2023/30] | Fees paid | Renewal fee | 07.09.2018 | Renewal fee patent year 03 | 11.02.2020 | Renewal fee patent year 04 | 17.02.2021 | Renewal fee patent year 05 | 25.02.2022 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 28.02.2023 | 07 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]US2014079740 (SALAMA ZOSER B [DE]) [Y] 1-15 * claims 2, 3 ** paragraphs [0243] , [ 244] , [ 246] *; | [XI] - ALLEN ET AL, "Ketamine Hydrochloride 10-mg Troches", U.S. PHARMACIST, (20090101), vol. 34, no. 11, pages 58 - 59, XP055409170 [X] 8-10,12 * page 1 * [I] 1-7,11,13-15 | [Y] - CHUI CHONG ET AL, "Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain", CLINICAL DRUG INVESTIGATION., NZ, (20090101), vol. 29, no. 5, doi:10.2165/00044011-200929050-00004, ISSN 1173-2563, pages 317 - 324, XP055345506 [Y] 1-15 * abstract * * page 318, column right * DOI: http://dx.doi.org/10.2165/00044011-200929050-00004 | International search | [A]US2015342947 (POLLARD SCOTT [US], et al) [A] 1-20 * ; entire document *; | [A]US2011038807 (PAPOLOS DEMITRI [US]) [A] 1-20 * ; entire document * | [X] - ALLEN, JR., "Ketamine Hydrochloride 10-mg Troches", U.S. Pharmacist, vol. 34, (20091119), pages 58 - 59, URL: https://www.uspharmacist.com/article/ketamine-hydrochloride-10-mg-troches, XP055409170 [X] 1-20 * ; pg. 1, para 1, pg. 2, para 1, pg. 3, para 3, pg. 4, para 1, title * | [A] - CHONG et al., "Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain", Clinical Drug Investigation, (20090000), vol. 29, pages 317 - 324, XP055345506 [A] 1-20 * ; entire document * DOI: http://dx.doi.org/10.2165/00044011-200929050-00004 |